HK1161123A1 - 含有奧曲肽微顆粒的藥物組合物 - Google Patents

含有奧曲肽微顆粒的藥物組合物

Info

Publication number
HK1161123A1
HK1161123A1 HK12101942.3A HK12101942A HK1161123A1 HK 1161123 A1 HK1161123 A1 HK 1161123A1 HK 12101942 A HK12101942 A HK 12101942A HK 1161123 A1 HK1161123 A1 HK 1161123A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
octreotide
microparticles
octreotide microparticles
pharmaceutical
Prior art date
Application number
HK12101942.3A
Other languages
English (en)
Inventor
Oliver Lambert
Michael Ausborn
Holger Petersen
Rolf Loeffler
Jean-Daniel Bonny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32299717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1161123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0226993A external-priority patent/GB0226993D0/en
Priority claimed from GB0227883A external-priority patent/GB0227883D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1161123A1 publication Critical patent/HK1161123A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
HK12101942.3A 2002-11-19 2006-02-16 含有奧曲肽微顆粒的藥物組合物 HK1161123A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0226993A GB0226993D0 (en) 2002-11-19 2002-11-19 Organic compounds
GB0227883A GB0227883D0 (en) 2002-11-29 2002-11-29 Organic compounds

Publications (1)

Publication Number Publication Date
HK1161123A1 true HK1161123A1 (zh) 2012-08-24

Family

ID=32299717

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101942.3A HK1161123A1 (zh) 2002-11-19 2006-02-16 含有奧曲肽微顆粒的藥物組合物

Country Status (17)

Country Link
US (6) US20040097419A1 (zh)
EP (2) EP1565161A2 (zh)
JP (2) JP2006514927A (zh)
KR (2) KR101240071B1 (zh)
AU (3) AU2003293700A1 (zh)
BR (1) BR0316421A (zh)
CA (1) CA2501978C (zh)
CO (1) CO5690533A2 (zh)
EC (1) ECSP055800A (zh)
ES (1) ES2577613T3 (zh)
HK (1) HK1161123A1 (zh)
MX (1) MXPA05005388A (zh)
NO (1) NO20052952L (zh)
PL (1) PL376015A1 (zh)
PT (1) PT2377519E (zh)
RU (2) RU2404748C2 (zh)
WO (1) WO2004045633A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773293B1 (en) 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
CA2576689C (en) * 2004-08-12 2012-10-09 Quest Pharmaceutical Services (Qps) Pharmaceutical compositions for controlled release delivery of biologically active compounds
CA2590696A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CA2601304C (en) * 2005-03-11 2010-08-17 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
SI1787658T1 (sl) 2005-11-10 2012-07-31 Chemi Spa Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona
RU2464972C2 (ru) * 2005-12-22 2012-10-27 Новартис Аг Композиции с замедленным высвобождением, включающие октреотид и два или более сополимера полилактида и гликолида
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
RU2463079C2 (ru) * 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Разделительные агенты для имплантируемого устройства и способы их применения
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
CA2729139C (en) * 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
EP3861986A1 (en) 2008-09-17 2021-08-11 Chiasma, Inc. Pharmaceutical compositions comprising polypeptides and related methods of delivery
EP2334288B1 (en) * 2008-09-18 2021-05-19 Evonik Corporation Microencapsulation process with solvent and salt
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
CN106727448B (zh) * 2016-12-12 2020-10-13 广州中大南沙科技创新产业园有限公司 醋酸奥曲肽干粉吸入制剂及其制备方法
WO2018156202A1 (en) 2017-02-27 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-psychotic composition and treatment methods
WO2019155396A1 (en) * 2018-02-07 2019-08-15 Dr. Reddy's Laboratories Limited Sustained release microspheres with low initial burst and methods of preparation thereof
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE19375086I2 (de) 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
DE3032345C2 (de) * 1980-08-28 1984-06-28 Mathias 4815 Schloss Holte Mitter Lagerung einer Rakel mit seitlich außerhalb der Schablone eines Siebdruckwerkes angeordneten Lagern
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
CA2050911C (en) * 1989-05-04 1997-07-15 Thomas R. Tice Encapsulation process and products therefrom
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9805417D0 (en) * 1998-03-14 1998-05-06 Core Technologies Limited Production of microparticles
US6204308B1 (en) * 1999-03-01 2001-03-20 Novartis Ag Organic compounds
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
CA2432900C (en) * 2000-12-21 2007-09-11 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophilic active agents

Also Published As

Publication number Publication date
AU2011200966A1 (en) 2011-03-24
JP2006514927A (ja) 2006-05-18
NO20052952L (no) 2005-08-15
ECSP055800A (es) 2005-08-11
CA2501978A1 (en) 2004-06-03
US20070122485A1 (en) 2007-05-31
ES2577613T3 (es) 2016-07-15
RU2005119632A (ru) 2006-05-10
KR101146471B1 (ko) 2012-05-21
US20040097419A1 (en) 2004-05-20
US20140323415A1 (en) 2014-10-30
AU2008200018A1 (en) 2008-01-31
AU2008200018B2 (en) 2010-12-09
CO5690533A2 (es) 2006-10-31
KR20120032537A (ko) 2012-04-05
EP2377519A3 (en) 2011-11-23
EP1565161A2 (en) 2005-08-24
KR20050086708A (ko) 2005-08-30
BR0316421A (pt) 2005-10-11
JP2011256185A (ja) 2011-12-22
US20220273574A1 (en) 2022-09-01
PT2377519E (pt) 2016-06-09
EP2377519A2 (en) 2011-10-19
MXPA05005388A (es) 2005-08-03
EP2377519B1 (en) 2016-03-23
KR101240071B1 (ko) 2013-03-06
PL376015A1 (en) 2005-12-12
CA2501978C (en) 2013-12-17
NO20052952D0 (no) 2005-06-16
AU2011200966B2 (en) 2013-08-01
WO2004045633A3 (en) 2005-01-13
US20200009056A1 (en) 2020-01-09
JP5784402B2 (ja) 2015-09-24
US20170281548A1 (en) 2017-10-05
RU2010144614A (ru) 2012-05-10
RU2404748C2 (ru) 2010-11-27
WO2004045633A2 (en) 2004-06-03
AU2003293700A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
HK1161123A1 (zh) 含有奧曲肽微顆粒的藥物組合物
GB2389530B (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
AU2003221497A1 (en) Pharmaceutical microparticles
HK1080717A1 (en) Pharmaceutical compositions with improved dissolution
IL164547A0 (en) Pharmaceutical composition
GB2391473B (en) Pharmaceutical compositions
AU2003250372A8 (en) Pharmaceutical composition
AU2003260803A8 (en) Sustained release pharmaceutical composition
GB2391809B (en) Pharmaceutical composition comprising honey
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
EP1478353A4 (en) PHARMACEUTICAL COMPOSITION WITH DELAYED RELEASE
AU2003267231A8 (en) Pharmaceutical compositions with improved dissolution
GB0213481D0 (en) Pharmaceutical compositions
HK1065477A1 (en) Pharmaceutical composition
GB0201520D0 (en) Pharmaceutical uses
GB0204392D0 (en) Pharmaceutical compound
PL355453A1 (en) Pharmaceutical agent
HU0200337D0 (en) Stabilised pharmaceutical composition
PL370907A1 (en) Pharmaceutical compositions
GB0217703D0 (en) Pharmaceutical composition
GB0213306D0 (en) Pharmaceutical composition
GB0228111D0 (en) Pharmaceutical composition
GB0225042D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231117